Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/d41591-020-00001-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The library is open: a scoping review on queer representation in psychedelic research.
Front Public Health
December 2024
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
The intersection of queer identity and psychedelics has not been thoroughly explored by the research community, historically or in the present day. With growing access to legal psychedelic therapies, it is essential that queer psychedelic experiences are understood sufficiently by clinicians in order to provide the most safe and effective care possible. Psychedelics and queerness are intricately related, and there is strong interest in the use of psychedelics for healing and identity development among queer populations.
View Article and Find Full Text PDFAnalytical and Pharmacological Characterization of 1-(Furan-2-Carbonyl)-LSD (1F-LSD) and Comparison With 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD).
Drug Test Anal
December 2024
Department of Psychiatry, University of California San Diego, La Jolla, USA.
The classical psychedelic drug (+)-lysergic acid diethylamide (LSD) continues to attract considerable multidisciplinary interest, and over the last eight decades, many derivatives and analogs of LSD have been synthesized. One site on the ergoline scaffold of LSD that has been frequently modified is the N-position, with the N-acylated LSD derivative 1-acetyl-LSD (1A-LSD, ALD-52) being one of the earliest examples. In more recent years, several other alkylcarbonyl- and cycloalkylcarbonyl-substituted LSD derivatives have been evaluated, including several distributed as research chemicals.
View Article and Find Full Text PDFExpert recommendations for Germany's integration of psychedelic-assisted therapy.
BMC Med Educ
October 2024
School of Psychology, University of Ottawa, Ottawa, ON, Canada.
As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psychedelic-assisted therapy (PAT) and supporting psychedelic drug research. This paper evaluates the necessary frameworks for implementing PAT in Germany, emphasizing the nation's potential leadership role within the European Union. With Australia having already approved MDMA and psilocybin for mental health indications, the Ukrainian government exploring MDMA treatment for war-related PTSD, and initial clinical trials involving MDMA and LSD with patients in Switzerland which restarted the restricted medical use of these substances around 2014, the medical authorization of psychedelics in these countries establishes precedent showcasing both the promise and challenges of researching and implementing PAT in nations where the substances were formally scheduled as illicit substances.
View Article and Find Full Text PDFEnhancing Methodological Approaches for Studying Health Effects of High-Concentration THC Products.
Am J Public Health
November 2024
Tianjing Li is with the Department of Ophthalmology, School of Medicine, University of Colorado Anschutz Medical Campus, and Department of Epidemiology, Colorado School of Public Health, Aurora. George Sam Wang is with the Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus. Lisa Bero is with the Center for Bioethics and Humanities, School of Medicine, University of Colorado Anschutz Medical Campus. Ashley Brooks-Russell is with the Department of Community and Behavioral Health, Colorado School of Public Health. Gregory Tung is with the Department of Health Systems, Management and Policy, Colorado School of Public Health. Jonathan M. Samet is with the Departments of Epidemiology and of Environmental and Occupational Health, Colorado School of Public Health.
For public health protection, informed decision-making relies on having a robust foundation of evidence concerning risks and their prevention. Application of an evidence-based framework depends on the availability of pertinent, scientifically sound data generated by well-directed and valid research endeavors. In this essay, we address the current state of research in humans and the evidential base concerning high-concentration delta-9-tetrahydrocannabinol (delta-9-THC) products, which are readily available in the United States.
View Article and Find Full Text PDFPsychedelics and the treatment of eating disorders: considerations for future research and practice.
J Eat Disord
October 2024
Department of Psychiatry, Dalhousie University, 5909 Veterans Memorial Lane, Halifax, NS, Canada.
Recent trials have shown promising results for the use of psychedelic-assisted therapies in treating severe refractory psychiatric illnesses, and there has been growing interest in examining the effectiveness of these therapies in treating eating disorders. To move forward in a safe, ethically sound, and scientifically rigorous manner, the field must address critical considerations. In this Comment article, we outline important risks and ethical considerations, along with methodological aspects that require careful consideration in the design of psychedelic-assisted therapy trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!